June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Effect of Intravitreal Injection of Iodoacetic Acid in Mice as a Model of Pharmacological Induced Monolateral Photoreceptor Degeneration
Author Affiliations & Notes
  • Sarah Roesch
    Ophthalmic clinic, University hospital RWTH, Aachen, Germany
  • Stephan Hesse
    Ophthalmic clinic, University hospital RWTH, Aachen, Germany
  • Christine Haselier
    Ophthalmic clinic, University hospital RWTH, Aachen, Germany
  • Babac Mazinani
    Ophthalmic clinic, University hospital RWTH, Aachen, Germany
  • Gernot Roessler
    Ophthalmic clinic, University hospital RWTH, Aachen, Germany
  • Christiane Pfarrer
    University of Veterinary medicine Hannover, Anatomical Institute, Hannover, Germany
  • Peter Walter
    Ophthalmic clinic, University hospital RWTH, Aachen, Germany
  • Footnotes
    Commercial Relationships Sarah Roesch, None; Stephan Hesse, None; Christine Haselier, None; Babac Mazinani, None; Gernot Roessler, None; Christiane Pfarrer, None; Peter Walter, Novartis (R), Bayer (R), Second Sight (R), Bayer (F), Novartis (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1954. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Sarah Roesch, Stephan Hesse, Christine Haselier, Babac Mazinani, Gernot Roessler, Christiane Pfarrer, Peter Walter; Effect of Intravitreal Injection of Iodoacetic Acid in Mice as a Model of Pharmacological Induced Monolateral Photoreceptor Degeneration. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1954.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To characterize the effect of intravitreal injection of Iodoacetic Acid (IAA) in comparison to its systemic application as a measure to induce monolateral photoreceptor degeneration.

Methods: Seven weeks old C57BL/6J mice received either intravitreal injections of IAA (25 animals) in different concentrations (between 0.1-1 mg/kg bodyweight (BW)) or systemic treatment [intraperitoneal (8 animals, 40-70 mg/kg BW) and intravenous (3 animals, 60-70 mg/kg BW)] and were observed in the following five weeks using ERG, OCT, and histology.

Results: Systemic application of IAA showed a mortality of 25% and toxic systemic effects with weight loss in the first two days of 10%. Intravenous application of IAA resulted in an extinction of the ERG and a thinning of the retina in the OCT. Intraperitoneal injection of IAA in mice showed no effect in the ERG or OCT for five weeks after injection. Animals that received intravitreal injections showed no weight loss after injection. Three to five days after injection the eyes developed cataracts ranging from 20% of cases at an IAA concentration of 0.1 mg/kg BW to 100% at an IAA concentration of 0.25 mg/kg BW. Higher intravitreal IAA concentrations lead to extinguished ERGs from 16% of cases at concentrations of 0.2 mg/kg BW to 90% at 0.25 mg/kg BW. Morphological signs of retinal degeneration after intravitreal injection were not observed, neither in the OCT nor in the histology.

Conclusions: Intravitreal injection of IAA leads to dense cataracts at lower concentrations than ERG changes occurred. ERG results must be interpreted carefully in the presence of induced cataracts. Morphological signs of retinal degeneration were not seen. In summary, the intravitreal injection of IAA did not prove to be an adequate model of monocular retinal degeneration in mice.

Keywords: 503 drug toxicity/drug effects • 494 degenerations/dystrophies • 689 retina: distal (photoreceptors, horizontal cells, bipolar cells)  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×